Immune Checkpoint Inhibitors Market - By Type (PD-1, PD-L1, CTLA-4), Application (Lung Cancer, Breast Cancer, Bladder Cancer, Melanoma, Cervical Cancer), End-use (Hospitals & Clinics, Cancer Centers), Global Forecast 2024 – 2032

Immune Checkpoint Inhibitors Market Size

Immune Checkpoint Inhibitors Market size was valued at USD 47.4 billion and is projected to grow at a CAGR of 16.7% from 2024 to 2032. This market is witnessing strong growth, primarily driven by the increasing global cancer prevalence and a rising demand for advanced, personalized cancer therapies.
 

Immune checkpoint inhibitors enhance the immune system's ability to identify and attack cancer cells. They have shown significant effectiveness against various cancers, such as melanoma, lung cancer, and renal cell carcinoma. The growing adoption of these therapies is supported by extensive clinical trials, favorable regulatory approvals, and their integration into established treatment protocols, all of which drive market growth.
 

Moreover, increased investments in oncology  research, along with a strong pipeline of new immune checkpoint inhibitors, are expected to sustain this market's growth. For example, in July 2021, the Rankin government pledged an investment of USD 18 million to improve cancer therapies, including immune checkpoint inhibitors. In 2023, the Cancer Research Institute allocated USD 28 million in grants specifically for cancer immunotherapy research. Such support from governmental and organizational entities is crucial in driving the immune checkpoint inhibitors market.
 

Immune checkpoint inhibitors are a specialized class of drugs in cancer therapy. They work by blocking proteins known as checkpoints, which are part of the immune system. These checkpoints help regulate the immune response, ensuring it does not harm normal cells. By blocking these checkpoints, immune checkpoint inhibitors enhance the ability of immune cells, especially T cells, to recognize and attack cancer cells.
 

Immune Checkpoint Inhibitors Market Trends

• The global rise in cancer cases significantly drives the market.
   
• According to the World Cancer Research Fund International, 2022 saw around 20 million new cancer cases worldwide, leading to roughly 9.7 million cancer-related deaths. Lung cancer topped the list with about 2.5 million new cases (12.4% of the total), followed closely by female breast cancer at 2.3 million cases (11.6%) and colorectal cancer with 1.9 million cases (9.6%).
   
• Moreover, the World Health Organization (WHO) forecasts a surge in new cancer cases, predicting a rise to 35 million by 2050, marking a 77% increase from 2022. This projected uptick is linked to an aging and growing population, coupled with lifestyle changes heightening cancer risk.
   
• With the rising prevalence of diverse cancer types, there's an escalating demand for innovative treatments. Immune checkpoint inhibitors, which bolster the body's immune response against cancer cells, have surfaced as pivotal therapeutic options.
   
• The escalating cancer burden has intensified research and development, leading to new approvals for immune checkpoint inhibitors and broader indications for existing ones. This surge in cancer cases is also expanding the patient base for these therapies, propelling market growth.
   
• Furthermore, the need for more effective and less toxic cancer treatments than traditional methods is amplifying the demand for immune checkpoint inhibitors, solidifying their role in contemporary oncology care.
   

Immune Checkpoint Inhibitors Market Analysis

Based on the type, the market is categorized into PD-1, PD-L1, CTLA-4, and other types. The PD-1 segment dominated the market with USD 34.7 billion in 2023.
 

• Due to its pivotal role in cancer immunotherapy, the PD-1 (Programmed Death-1) segment commands a significant share of the market.
   
• PD-1 inhibitors, including pembrolizumab and nivolumab, have shown impressive efficacy across various cancers, such as melanoma, non-small cell lung cancer, and renal cell carcinoma. Their success stems from their capability to bolster the immune system's attack on tumor cells by obstructing the PD-1 pathway, a tactic often leveraged by tumors to dodge immune detection.
   
• Strong clinical results, an expanding range of indications, and increasing integration into oncology practices solidify the dominant market position of PD-1 inhibitors, establishing them as foundational elements in cancer treatment.
   

The immune checkpoint inhibitors market is segmented by application into lung cancer, breast cancer, bladder cancer, melanoma, cervical cancer, Hodgkin lymphoma, colorectal cancer, and other applications. In 2023, the lung cancer segment led the market, commanding a 25.1% share.
 

• Lung cancer's dominant market share in immune checkpoint inhibitors stems from the disease's significant burden and the therapies' proven efficacy in enhancing patient outcomes.
   
• For instance, according to the Lung Cancer Research Foundation, in 2023, the U.S. saw 238,340 new lung cancer diagnoses, resulting in approximately 127,070 fatalities. The lifetime diagnosis risk stands at 1 in 16 for men and 1 in 17 for women.
   
• Immune checkpoint inhibitors, targeting proteins like PD-1, PD-L1, and CTLA-4, have shown notable success in treating non-small cell lung cancer (NSCLC), the predominant lung cancer type.
   
• The combination of lung cancer's high prevalence and the growing acceptance of immunotherapy drugs as a primary treatment fuels the robust market presence of these inhibitors.
   
• Moreover, ongoing research and clinical trials are broadening the application of immune checkpoint inhibitors across various lung cancer stages, reinforcing their market leadership.

Segmented by end-use, the immune checkpoint inhibitors market includes hospitals & clinics, cancer centers, and academic & research institutes. In 2023, hospitals & clinics led the market and are projected to grow at a CAGR of 16.5% from 2024 to 2032.
 

• This dominant market position is attributed to the prevalent use of these therapies in hospitals and clinics. Here, specialized oncology departments and expert healthcare professionals ensure precise diagnosis, tailored treatment plans, and continuous patient care.
   
• Moreover, the presence of cutting-edge medical infrastructure, holistic cancer treatment programs, and the capability to address the intricate side effects of immunotherapy further bolster hospitals and clinics' leading role in this market.
   

In 2023, the North American immune checkpoint inhibitors market was valued at USD 22.9 billion, with projections indicating robust growth at a CAGR of 16.8% from 2024 to 2032.
 

• The North American market is bolstered by the presence of leading pharmaceutical companies, actively engaged in both the development and commercialization of immune checkpoint inhibitors. Furthermore, the region's advantageous regulatory landscape, coupled with strong backing from both governmental and non-governmental organizations for cancer treatment initiatives, solidifies its dominant market position.
   
• Moreover, the escalating prevalence of cancer in the region amplifies the demand for these treatments. For example, the American Cancer Society projects a continued rise in the cancer burden for 2024, estimating around 2,170,450 new cases in the U.S. and Canada combined. This significant patient population not only underscores the urgency for these treatments but also incentivizes healthcare providers and pharmaceutical firms to prioritize the development and accessibility of advanced cancer therapies.
   

In 2023, the U.S. immune checkpoint inhibitors market was valued at USD 20.7 billion.
 

• The U.S. stands as a dominant force in the immune checkpoint inhibitors arena, a status achieved through its advanced healthcare infrastructure, substantial R&D investments, and a promising pipeline of innovative therapies.
   
• The nation's leadership in both biotechnology and pharmaceuticals, combined with a pronounced prevalence of cancer cases, has cultivated a fertile ground for the growth of immune checkpoint inhibitors.
   
• Moreover, the presence of major pharmaceutical players and established clinical trial networks fortifies the development and market entry of these therapies.
•  

The Asia Pacific region is set to experience a notable growth spurt, projected at a CAGR of 17% during the forecast period.
 

• Key drivers include swift advancements in healthcare infrastructure and a heightened emphasis on cancer research.
   
• The surging cancer prevalence, paired with an increasing awareness and adoption of modern treatment modalities, amplifies the demand for immune checkpoint inhibitors.
   
• Furthermore, favorable government policies, escalating investments in the biotech and pharmaceutical domains, and a vast patient demographic bolster the region's growth trajectory.
   
• With the introduction of novel treatment protocols and active clinical trials, the Asia Pacific is solidifying its stature in the global immune checkpoint inhibitors arena.
   

India's immune checkpoint inhibitors market is poised for significant growth.
 

• As highlighted in an article from the Indian Journal of Public Health, cancer incidences in India have been steadily climbing. Reported cases rose from approximately 1.39 million in 2020 to 1.46 million in 2022, with projections suggesting a leap to 1.57 million by 2025. This rising patient base, combined with improving access and affordability of advanced therapies, fuels the market's growth.
   
• Moreover, India's bolstering healthcare infrastructure and surging investments in biotech and pharmaceuticals are catalyzing the demand for sophisticated cancer treatments.
   
• As India carves out a more pronounced role in the global healthcare narrative, its market stands poised to leverage both domestic advancements and international partnerships, aiming for a significant global presence.
   

Immune Checkpoint Inhibitors Market Share

The competitive landscape of the market is characterized by intense rivalry among leading pharmaceutical companies and biotech firms. Major players such as Bristol-Myers Squibb, Merck & Co., and Roche dominate the market with their flagship products like Opdivo, Keytruda, and Tecentriq, respectively. These companies are heavily investing in ongoing clinical trials and research to expand the indications for their existing therapies and develop novel checkpoint inhibitors.
 

Additionally, emerging biotech firms are entering the market with innovative approaches and novel targets, contributing to a dynamic and rapidly evolving competitive environment. Strategic collaborations, mergers and acquisitions, and significant investments in research and development are key strategies employed by these companies to maintain their competitive edge and drive growth in the market.
 

Immune Checkpoint Inhibitors Market Companies

Few of the prominent players operating in immune checkpoint inhibitors industry include:

• AstraZeneca PLC
• BeiGene, Ltd.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Incyte Corporation
• Immutep Limited
• Merck & Co., Inc.
• Regeneron Pharmaceuticals, Inc.
• Sanofi
• Shanghai Junshi Biosciences Co., Ltd.
   

Immune Checkpoint Inhibitors Market News:

• In October 2023, Bristol Myers Squibb, received U.S. FDA approval of Opdivo (nivolumab) for treatment of completely resected stage IIB or Stage IIC melanoma in adult and pediatric patients aged 12 years and older. This marks a significant expansion of Opdivo's indications, as it is now recognized as the only PD-1 inhibitor approved for adjuvant treatment in these earlier stages of melanoma, alongside its existing approvals for more advanced stages of the disease. This approval enhanced the company's position in the oncology market.
   
• In January 2023, Teon Therapeutics announced a clinical trial collaboration with Merck & Co. to evaluate the efficacy of TT-816, an oral immune response modifier, in combination with KEYTRUDA (pembrolizumab).
   

The immune checkpoint inhibitors market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• PD-1
• PD-L1
• CTLA-4
• Other types

Market, By Application

• Lung cancer
• Breast cancer
• Bladder cancer
• Melanoma
• Cervical cancer
• Hodgkin lymphoma
• Colorectal cancer
• Other applications

Market, By End-use

• Hospitals & clinics
• Cancer centers
• Academic and research institutes

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa